Prognostic Factors and Survival in Non-Small Cell Lung Cancer Patients Treated with Chemoradiotherapy
DOI:
https://doi.org/10.3889/oamjms.2015.003Keywords:
prognostic factors, performance status, stage, weight loss, conformal radiotherapy, sequential and concurrent chemoradiotherapyAbstract
BACKGROUND: According to the literature, performance status, stage-tumor dimension and nodal status, weight loss, were the most important prognostic factors for survival in patients with locally advanced non-small cell lung cancer.
AIM: To evaluate the treatment results and the prognostic variables in our patients treated with sequential and concurrent chemoradiotherapy.
MATERIAL AND METHODS: In the study 85 patients were randomly assigned to one of the two treatment arms. In the sequential arm, 45 patients had previously received sequential chemotherapy with 4 cycles of and etoposide followed by conformal radiotherapy (RT). In the second concurrent group, 40 patients received concomitant chemotherapy of cisplatine and etoposide and conformal RT, followed by two cycles of consolidation chemotherapy of carboplatine and etoposide. We described all phases of the conformal three dimensional (3-D) RT.
RESULTS: From October 2005 to March 2008, 93 patients were enrolled. Eight patients were not eligible, seven had stage IV and one patient had pleural effusion. They were all initially considered to have stage IIIB disease. Â The median survival was 13 months for the patients in the sequential arm and 19 months for those in the concurrent treatment arm. The differences were statistically significant (log-rank test p=0.0039). The disease-free survival was 9 months in the sequential arm and 16 months in the concurrent treatment group. The differences were statistically significant (log-rank test p=0.0023). We found that the following prognostic factors significantly influenced the survival in lung cancer patients treated with conservative method: - age, p<0.05; - performant status, p<0.001; - weight loss, p<0.001; tumor dimension, p<0.05; and - nodal involvement, p<0.05.
CONCLUSION: In our study, the dose-limiting toxicity, esophagitis was reduced by performing conformal radiotherapy. Conformal thoracic radiotherapy and new radiotherapy technics, such as respiratory gated radiotherapy, allow dose escalating and may probably improve survival and local control in lung cancer patients.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy Alone versus combined chemotherapy and radiotherapy in unrespectable NSCLC: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991; 83: 417-423. DOI: https://doi.org/10.1093/jnci/83.6.417
NSCLC Collaborative Group Chemotherapy in NSCLC. A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995; 311: 899-909. DOI: https://doi.org/10.1136/bmj.311.7010.899
Cfriess G, Balkadi M, Harvey WH, et al. Concurrent cisplatin and etoposide with radiotherapy in locally advanced NSCLC. Cancer Treat Rep. 1987; 71: 681-684.
Stanly KZ. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980; 65:25.
Gandara DR, Chansky K, Alban KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB NSCLC: Phase II Southwest Oncology Group phase II study, SWOG s9504. J Clin Oncol. 2003; 21: 2004-2010. DOI: https://doi.org/10.1200/JCO.2003.04.197
Choy H, Curran WJ, Scot CB, et al. Preliminary report of locally Advanced Multimodality Protocol (LAMP): ACR 427: A randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin and thoracic radiation (TRT) for patients with locally advanced NSCLC (LA-NSCLC). Proc Am Soc Clin Oncol. 2002; 21: 291a (abstr 1160).
Curran WJ, Scott CB, Langer CJ et al. Long-term benefit is observed in phase II comparison of sequential vs concurrent chemoradiotherapy for patients with unrespectable stage III NSCLC: RTOG 94-10. Proc Am Soc Clin Oncol. 2003; 22: 621a (abstr 2499).
Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unrespectable stage III NSCLC. J Clinic Oncol. 1999; 17: 2692-2699. DOI: https://doi.org/10.1200/JCO.1999.17.9.2692
Albain KS, Crowwley JJ, Turrisi AT, et al. Concurrent cisplatin, etoposide and chest radiotherapy in pathologic stage IIIB NSCLC: A Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002; 20: 3454-3460. DOI: https://doi.org/10.1200/JCO.2002.03.055
Xiong Wei, H. Liu, Tucker S, et al. Risk factors for acute esophagitis in NSCLC patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006; 66: 100-107. DOI: https://doi.org/10.1016/j.ijrobp.2006.04.022
Sealy R., Lagakos S., Barkly T, et al. Radiotherapy of regional epidermoid carcinoma of the lung. Cancer. 1982; 49:1338-1345. DOI: https://doi.org/10.1002/1097-0142(19820401)49:7<1338::AID-CNCR2820490705>3.0.CO;2-Y
Jemal A Thomas A, Murray T, et al. Cancer statistics 2002. CA Cancer J Clin. 2002; 52:23-47. DOI: https://doi.org/10.3322/canjclin.52.1.23
Travis WD, Colby TV, Corrin B, et al. Histological Typing of Lung Tumors. Geneva Switzerland World Health Organization, 1999. DOI: https://doi.org/10.1007/978-3-642-60049-4
Patz EF, Rossi S, Harpole DH et al. Correlation of tumor size and survival in patient with advanced non-small cell lung cancer. Chest. 2000; 117:1568-1571. DOI: https://doi.org/10.1378/chest.117.6.1568
Janssen-Heijneng MLG, Gatta G, Forman D, et al. Variation in survival of patients with lung cancer in Europe, 1985-1989. Eur J Cancer. 1998; 34:2191-2196. DOI: https://doi.org/10.1016/S0959-8049(98)00312-8
Merrill RM, Henson DE, Barnes M Travis WD, Colby TV, Corrin B, et al. Survival among patients with carcinoma of the lung. Chest. 1999; 166:697-703. DOI: https://doi.org/10.1378/chest.116.3.697
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
